One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. - Wikidata - wikimedia - TriplyDB

One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.

One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.

http://www.wikidata.org/entity/Q34636998

about

Targeted therapy of gastrointestinal stromal tumours Targeting gastrointestinal stromal tumors: the role of regorafenib Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions Endoscopic treatment for gastrointestinal stromal tumor: Advantages and hurdles The GIST of targeted therapy for malignant melanoma Primary gastrointestinal stromal tumors: Current advances in diagnostic biomarkers, prognostic factors and management of its duodenal location Follow-up in soft tissue sarcomas Clinical practice guidelines for patients with gastrointestinal stromal tumor in Taiwan Current management and prognostic features for gastrointestinal stromal tumor (GIST)Cardiovascular toxicity of multi-tyrosine kinase inhibitors in advanced solid tumors: a population-based observational study Key messages from the BFR14 trial of the French Sarcoma Group.Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications.A nomogram to predict disease-free survival after surgical resection of GIST [Hemato-oncological diseases].Early outcomes of exon 11 mutants in GIST treated with standard dose Imatinib.Endoscopic ultrasound-guided cutting of holes and deep biopsy for diagnosis of gastric infiltrative tumors and gastrointestinal submucosal tumors using a novel vertical diathermic loop.UK clinical practice guidelines for the management of gastrointestinal stromal tumours (GIST).Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.SLUG transcription factor: a pro-survival and prognostic factor in gastrointestinal stromal tumour Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial Imatinib: a breakthrough of targeted therapy in cancer.Evaluation of high-risk clinicopathological indicators in gastrointestinal stromal tumors for prognosis and imatinib treatment outcome.Efficacy and economic value of adjuvant imatinib for gastrointestinal stromal tumors Prognostic value of Ki67 index in gastrointestinal stromal tumors.Targeted therapy for cancer: the gastrointestinal stromal tumor model.Cost Effectiveness of Universal Hepatitis B Virus Screening in Patients Beginning Chemotherapy for Sarcomas or GI Stromal Tumors.Optimizing adherence to adjuvant imatinib in gastrointestinal stromal tumor.CTHRC1 acts as a prognostic factor and promotes invasiveness of gastrointestinal stromal tumors by activating Wnt/PCP-Rho signaling.Gastrointestinal stromal tumors (GISTs): point mutations matter in management, a review.It's about time: lessons for solid tumors from chronic myelogenous leukemia therapy Practical aspects of risk assessment in gastrointestinal stromal tumors.In vivo fluorescence imaging of gastrointestinal stromal tumors using fluorophore-conjugated anti-KIT antibody Survival of gastrointestinal stromal tumor patients in the imatinib era: life raft group observational registry.Adjuvant treatment of GIST: patient selection and treatment strategies.Approval summary: imatinib mesylate for one or three years in the adjuvant treatment of gastrointestinal stromal tumors.Adjuvant therapy for high-risk gastrointestinal stromal tumour: considerations for optimal management.Complete pathological response to Imatinib mesylate in an extraintestinal gastrointestinal stromal tumor Clinical and therapeutic considerations of GIST Prediction of Tumor Recurrence in Patients with Non-Gastric Gastrointestinal Stromal Tumors Following Resection according to the Modified National Institutes of Health Criteria.A high risk group in the modified national institutes of health consensus criteria for the gastrointestinal stromal tumor: a clear indication of the adjuvant imatinib.

P2860

Q26745633-CC2482EC-691E-4D70-B5FB-AEFF436C4D76 Q26747162-FAFE6904-7BF8-4941-988D-91B8DA97D2BA Q26799387-0678BBB5-F115-4D12-B065-03EA983DD6E7 Q26822890-74F57776-642D-4DC9-A1FF-7CDF57E36093 Q26827092-BF71D2C9-0B58-4B71-823D-02962D70C942 Q26829970-EB7C9A42-CE87-45C7-AE60-90DFD0138D43 Q26830942-FB39803C-8FCC-457E-907A-E91266916C31 Q27027632-25E72C06-B728-45B6-9A3B-65A04EFD1B82 Q28391684-15335218-AA83-4382-A250-2B69346F0F5E Q28545130-946D13A2-5998-45A2-A79D-58E3DD254F94 Q30245384-180B482A-849A-4FA4-9E40-61D95305895B Q30245586-B06FA111-DE8D-4436-B2E4-95956BC65860 Q30366151-31FB5A63-6D10-493E-BEEE-D1978ABE2C28 Q33410075-6D441C40-5419-415D-8FE1-BA3409162A22 Q33575310-FF74717A-224F-49E1-9B4B-E2029975F384 Q33599569-88853C46-69D8-450B-B4E2-846A7062E064 Q33612778-2B4A2B92-85DA-4A95-A539-6F64FB2BA551 Q33633409-84F4FD8A-CE9F-4BFF-ABD1-DB8652F16E4B Q33639728-D23874DA-D376-412F-AC81-8EFCA8C3597E Q33699901-4E89369C-C31D-4A84-93AA-72AD4CB59EC4 Q33747261-B8EB2497-1571-42C0-A55A-748A5DFABE83 Q33756596-EB90FABF-AFE8-4E6F-9F07-54C31EF2BB7F Q33777447-10C3E922-9154-4FF4-9FFB-7C04E85BE47E Q33802994-DF912B4D-33E7-4242-BC11-65DCD6C8ABF6 Q33807742-1B04107A-AE9A-456E-9AB5-EBB550F5D031 Q33872813-F76935D5-30C6-44B9-9656-07363FFD49BB Q33885999-70CBB624-1040-48D9-BA25-5C7A9341F4AB Q33891101-4DEA48B2-744F-4C1C-952D-44DF6C256CD9 Q33895608-D5429311-C584-4946-AAB4-D698811B0D90 Q33936071-5BF958CA-5333-4905-9D5A-246FE16F74A4 Q34021413-A2CC683E-323E-4BDD-B502-C49B7C7702E7 Q34024845-304404BB-96E9-4129-927A-1BFDAB453199 Q34202009-E0C9483D-F0FD-411B-9D16-EF769DFE613A Q34270274-92873DE4-2D13-40E6-888A-E924B4F966E2 Q34277908-A448AF6A-319D-41C5-94C2-70F4451F6EEC Q34300784-4396F716-2726-446D-81A8-E9FCE24B2221 Q34305765-A46BF4C1-FF0A-4ACC-9D41-A5D05F016B69 Q34341168-B477D3EE-4323-40B1-9756-DCC21C12F6B8 Q34378739-B1200A1D-ECD0-4810-8B24-6941A94EE8A0 Q34378749-9870F43D-3E06-4E28-80C2-809EA73D63DF

P2860

One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.

http://www.wikidata.org/entity/Q34636998

description

2012 nî lūn-bûn

@nan

2012 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մարտին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

One vs three years of adjuvant ...... mal tumor: a randomized trial.

@ast

One vs three years of adjuvant ...... mal tumor: a randomized trial.

@en

One vs three years of adjuvant ...... mal tumor: a randomized trial.

@nl

type

label

One vs three years of adjuvant ...... mal tumor: a randomized trial.

@ast

One vs three years of adjuvant ...... mal tumor: a randomized trial.

@en

One vs three years of adjuvant ...... mal tumor: a randomized trial.

@nl

prefLabel

One vs three years of adjuvant ...... mal tumor: a randomized trial.

@ast

One vs three years of adjuvant ...... mal tumor: a randomized trial.

@en

One vs three years of adjuvant ...... mal tumor: a randomized trial.

@nl

P1433

Q34636998-9E2E35EB-1856-4BCB-AB4D-FF2C3D0FC055

P1476

Q34636998-2521C6ED-6139-40EB-BF8D-07073EBB5177

P2093

Q34636998-06BCCA17-6092-4066-B1D5-CFDAEAD751B9

Q34636998-0A6C7991-FD91-41FE-9A9F-94221FCBF589

Q34636998-15D9404D-FFBE-448D-94C2-AC9DEE96D629

Q34636998-300FFCB6-CEEE-492D-AEC9-2E90C63A3337

Q34636998-66C96F4D-4966-4F9F-87E7-277CAE547EB0

Q34636998-7E6B6EBE-06A6-41C6-99BB-25B74D457A53

Q34636998-7F405AA0-87A5-41B9-9929-8F0C49E160D9

Q34636998-83218D63-2BD1-453F-9596-839216FADD3E

Q34636998-86F95199-C40A-4C53-A735-222C81961EE5

Q34636998-A96DC9AB-1438-4403-B908-1C08574C3D09

P304

Q34636998-8B637F5F-9824-4B88-99EB-60A3ED248A78

P31

Q34636998-17D20FEF-6924-4137-B260-DBB26C4F8D74

P356

Q34636998-9FD06BEB-58E6-4FA4-AC9E-B86C19C929EF

P407

Q34636998-6C023292-2406-4417-A970-7011A126AC67

P433

Q34636998-27E83128-F226-47F9-B06C-BFAEBF32D87C

P478

Q34636998-5F3C6533-4AD5-426D-955D-539BFC4167AD

P50

Q34636998-3C76A3A1-8F8F-4489-9D2D-CFDE1EDD43F3

Q34636998-73983057-01FD-4EC7-A0C1-EB5FE50CCD7D

Q34636998-C9F1D4C5-E8F5-44A9-82B8-07F330DE2CFD

P577

Q34636998-CA25DC0F-2407-4F29-886F-436B1DB2C4DC

P698

Q34636998-FBCBD15A-6008-4A06-B931-A1E011B32EC1

P356

P1433

Journal of the American Medical Association

P1476

One vs three years of adjuvant ...... omal tumor: a randomized trial

@en

P2093

Bengt Nilsson

http://www.w3.org/2001/XMLSchema#string

Daniel Pink

http://www.w3.org/2001/XMLSchema#string

Eva Wardelmann

http://www.w3.org/2001/XMLSchema#string

Giuliano Ramadori

http://www.w3.org/2001/XMLSchema#string

Heikki Joensuu

http://www.w3.org/2001/XMLSchema#string

Jochen Schütte

http://www.w3.org/2001/XMLSchema#string

Justus Duyster

http://www.w3.org/2001/XMLSchema#string

Jörg T Hartmann

http://www.w3.org/2001/XMLSchema#string

Kirsten Sundby Hall

http://www.w3.org/2001/XMLSchema#string

Maarit Sarlomo-Rikala

http://www.w3.org/2001/XMLSchema#string

P304

1265-1272

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMA.2012.347

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

307

http://www.w3.org/2001/XMLSchema#string

P50

Sebastian Bauer

P577

2012-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22453568

http://www.w3.org/2001/XMLSchema#string